Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash from Investing Activities (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash from Investing Activities for 16 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 14511.11% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $287000.0, a 106.81% increase, with the full-year FY2024 number at -$4.1 million, down 2469.38% from a year prior.
  • Cash from Investing Activities was $1.3 million for Q3 2025 at Plus Therapeutics, up from -$4.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $3.6 million in Q1 2025 to a low of -$4.6 million in Q2 2025.
  • A 5-year average of -$305687.5 and a median of -$37500.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 34463.64% in 2024, then soared 14511.11% in 2025.
  • Plus Therapeutics' Cash from Investing Activities stood at -$84000.0 in 2021, then skyrocketed by 86.9% to -$11000.0 in 2022, then tumbled by 281.82% to -$42000.0 in 2023, then soared by 252.38% to $64000.0 in 2024, then soared by 1926.56% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Cash from Investing Activities are $1.3 million (Q3 2025), -$4.6 million (Q2 2025), and $3.6 million (Q1 2025).